In this regard, any promotion of COVID19 vaccination by the medical community, especially by cardiologists, is essential for the patients we see in our clinics and hospitals every day. As vaccine-preventable diseases, the association between influenza and cardiovascular complications has been investigated extensively. The risk of hospitalization for acute myocardial infarction is substantially higher in the first seven days following laboratory-confirmed influenza, with incidence ratios ranging from 6.05 to 8.89. influenza vaccines protect against acute myocardial infarction by about 29%. The effectiveness of this method is comparable to or even better than the effectiveness of secondary preventive therapies like:
- Statins (prevention rate approximately 36%),
- Antihypertensives (prevention rate about 15–18%),
- Smoking cessation (prevention rate about 26%).
The beneficial effects of influenza vaccination are of the same magnitude as those of statins, antihypertensives, and quitting smoking. The American College of Cardiology published a health policy statement this year recommending that the COVID-19 vaccine be prioritized for heart disease patients with the highest risk. Patients should be informed of the safety of the influenza vaccine and the low perceived risk of the disease when promoting vaccination against influenza.
Furthermore, recent studies suggest debunking misinformation is most effective by stating the truth, mentioning the false claim, and then restating the truth. To implement the flu vaccine into routine cardiac patient care, this Point of View paper serves as a call to action.